Eintrag weiter verarbeiten
The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States
Gespeichert in:
| Zeitschriftentitel: | Epidemiology and Infection |
|---|---|
| Personen und Körperschaften: | , , , |
| In: | Epidemiology and Infection, 132, 2004, 6, S. 1055-1063 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Cambridge University Press (CUP)
|
| Schlagwörter: |
| author_facet |
MUENNIG, P. PALLIN, D. CHALLAH, C. KHAN, K. MUENNIG, P. PALLIN, D. CHALLAH, C. KHAN, K. |
|---|---|
| author |
MUENNIG, P. PALLIN, D. CHALLAH, C. KHAN, K. |
| spellingShingle |
MUENNIG, P. PALLIN, D. CHALLAH, C. KHAN, K. Epidemiology and Infection The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States Infectious Diseases Epidemiology |
| author_sort |
muennig, p. |
| spelling |
MUENNIG, P. PALLIN, D. CHALLAH, C. KHAN, K. 0950-2688 1469-4409 Cambridge University Press (CUP) Infectious Diseases Epidemiology http://dx.doi.org/10.1017/s0950268804003000 <jats:p>The presumptive treatment of parasitosis among immigrants with albendazole has been shown to save both money and lives, primarily via a reduction in the burden of <jats:italic>Strongyloides stercoralis</jats:italic>. Ivermectin is more effective than albendazole, but is also more expensive. This coupled with confusion surrounding the cost-effectiveness of guiding therapy based on eosinophil counts has led to disparate practices. We used the newly arrived year 2000 immigrant population as a hypothetical cohort in a decision analysis model to examine the cost-effectiveness of various interventions to reduce parasitosis among immigrants. When the prevalence of <jats:italic>S. stercoralis</jats:italic> is greater than 2%, the incremental cost-effectiveness ratios of all presumptive treatment strategies were similar. Ivermectin is associated with an incremental cost-effectiveness ratio of $1700 per QALY gained for treatment with 12 mg ivermectin relative to 5 days of albendazole when the prevalence is 10%. Any presumptive treatment strategy is cost-effective when compared with most common medical interventions.</jats:p> The cost-effectiveness of ivermectin <i>vs</i>. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States Epidemiology and Infection |
| doi_str_mv |
10.1017/s0950268804003000 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAxNy9zMDk1MDI2ODgwNDAwMzAwMA |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAxNy9zMDk1MDI2ODgwNDAwMzAwMA |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
Cambridge University Press (CUP), 2004 |
| imprint_str_mv |
Cambridge University Press (CUP), 2004 |
| issn |
0950-2688 1469-4409 |
| issn_str_mv |
0950-2688 1469-4409 |
| language |
English |
| mega_collection |
Cambridge University Press (CUP) (CrossRef) |
| match_str |
muennig2004thecosteffectivenessofivermectinvsalbendazoleinthepresumptivetreatmentofstrongyloidiasisinimmigrantstotheunitedstates |
| publishDateSort |
2004 |
| publisher |
Cambridge University Press (CUP) |
| recordtype |
ai |
| record_format |
ai |
| series |
Epidemiology and Infection |
| source_id |
49 |
| title |
The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States |
| title_unstemmed |
The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States |
| title_full |
The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States |
| title_fullStr |
The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States |
| title_full_unstemmed |
The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States |
| title_short |
The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States |
| title_sort |
the cost-effectiveness of ivermectin <i>vs</i>. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the united states |
| topic |
Infectious Diseases Epidemiology |
| url |
http://dx.doi.org/10.1017/s0950268804003000 |
| publishDate |
2004 |
| physical |
1055-1063 |
| description |
<jats:p>The presumptive treatment of parasitosis among immigrants with albendazole has been shown to save both money and lives, primarily via a reduction in the burden of <jats:italic>Strongyloides stercoralis</jats:italic>. Ivermectin is more effective than albendazole, but is also more expensive. This coupled with confusion surrounding the cost-effectiveness of guiding therapy based on eosinophil counts has led to disparate practices. We used the newly arrived year 2000 immigrant population as a hypothetical cohort in a decision analysis model to examine the cost-effectiveness of various interventions to reduce parasitosis among immigrants. When the prevalence of <jats:italic>S. stercoralis</jats:italic> is greater than 2%, the incremental cost-effectiveness ratios of all presumptive treatment strategies were similar. Ivermectin is associated with an incremental cost-effectiveness ratio of $1700 per QALY gained for treatment with 12 mg ivermectin relative to 5 days of albendazole when the prevalence is 10%. Any presumptive treatment strategy is cost-effective when compared with most common medical interventions.</jats:p> |
| container_issue |
6 |
| container_start_page |
1055 |
| container_title |
Epidemiology and Infection |
| container_volume |
132 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792337590341337091 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:18:33.643Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=The+cost-effectiveness+of+ivermectin+vs.+albendazole+in+the+presumptive+treatment+of+strongyloidiasis+in+immigrants+to+the+United+States&rft.date=2004-12-01&genre=article&issn=1469-4409&volume=132&issue=6&spage=1055&epage=1063&pages=1055-1063&jtitle=Epidemiology+and+Infection&atitle=The+cost-effectiveness+of+ivermectin+%3Ci%3Evs%3C%2Fi%3E.+albendazole+in+the+presumptive+treatment+of+strongyloidiasis+in+immigrants+to+the+United+States&aulast=KHAN&aufirst=K.&rft_id=info%3Adoi%2F10.1017%2Fs0950268804003000&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792337590341337091 |
| author | MUENNIG, P., PALLIN, D., CHALLAH, C., KHAN, K. |
| author_facet | MUENNIG, P., PALLIN, D., CHALLAH, C., KHAN, K., MUENNIG, P., PALLIN, D., CHALLAH, C., KHAN, K. |
| author_sort | muennig, p. |
| container_issue | 6 |
| container_start_page | 1055 |
| container_title | Epidemiology and Infection |
| container_volume | 132 |
| description | <jats:p>The presumptive treatment of parasitosis among immigrants with albendazole has been shown to save both money and lives, primarily via a reduction in the burden of <jats:italic>Strongyloides stercoralis</jats:italic>. Ivermectin is more effective than albendazole, but is also more expensive. This coupled with confusion surrounding the cost-effectiveness of guiding therapy based on eosinophil counts has led to disparate practices. We used the newly arrived year 2000 immigrant population as a hypothetical cohort in a decision analysis model to examine the cost-effectiveness of various interventions to reduce parasitosis among immigrants. When the prevalence of <jats:italic>S. stercoralis</jats:italic> is greater than 2%, the incremental cost-effectiveness ratios of all presumptive treatment strategies were similar. Ivermectin is associated with an incremental cost-effectiveness ratio of $1700 per QALY gained for treatment with 12 mg ivermectin relative to 5 days of albendazole when the prevalence is 10%. Any presumptive treatment strategy is cost-effective when compared with most common medical interventions.</jats:p> |
| doi_str_mv | 10.1017/s0950268804003000 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAxNy9zMDk1MDI2ODgwNDAwMzAwMA |
| imprint | Cambridge University Press (CUP), 2004 |
| imprint_str_mv | Cambridge University Press (CUP), 2004 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 0950-2688, 1469-4409 |
| issn_str_mv | 0950-2688, 1469-4409 |
| language | English |
| last_indexed | 2024-03-01T15:18:33.643Z |
| match_str | muennig2004thecosteffectivenessofivermectinvsalbendazoleinthepresumptivetreatmentofstrongyloidiasisinimmigrantstotheunitedstates |
| mega_collection | Cambridge University Press (CUP) (CrossRef) |
| physical | 1055-1063 |
| publishDate | 2004 |
| publishDateSort | 2004 |
| publisher | Cambridge University Press (CUP) |
| record_format | ai |
| recordtype | ai |
| series | Epidemiology and Infection |
| source_id | 49 |
| spelling | MUENNIG, P. PALLIN, D. CHALLAH, C. KHAN, K. 0950-2688 1469-4409 Cambridge University Press (CUP) Infectious Diseases Epidemiology http://dx.doi.org/10.1017/s0950268804003000 <jats:p>The presumptive treatment of parasitosis among immigrants with albendazole has been shown to save both money and lives, primarily via a reduction in the burden of <jats:italic>Strongyloides stercoralis</jats:italic>. Ivermectin is more effective than albendazole, but is also more expensive. This coupled with confusion surrounding the cost-effectiveness of guiding therapy based on eosinophil counts has led to disparate practices. We used the newly arrived year 2000 immigrant population as a hypothetical cohort in a decision analysis model to examine the cost-effectiveness of various interventions to reduce parasitosis among immigrants. When the prevalence of <jats:italic>S. stercoralis</jats:italic> is greater than 2%, the incremental cost-effectiveness ratios of all presumptive treatment strategies were similar. Ivermectin is associated with an incremental cost-effectiveness ratio of $1700 per QALY gained for treatment with 12 mg ivermectin relative to 5 days of albendazole when the prevalence is 10%. Any presumptive treatment strategy is cost-effective when compared with most common medical interventions.</jats:p> The cost-effectiveness of ivermectin <i>vs</i>. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States Epidemiology and Infection |
| spellingShingle | MUENNIG, P., PALLIN, D., CHALLAH, C., KHAN, K., Epidemiology and Infection, The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States, Infectious Diseases, Epidemiology |
| title | The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States |
| title_full | The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States |
| title_fullStr | The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States |
| title_full_unstemmed | The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States |
| title_short | The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States |
| title_sort | the cost-effectiveness of ivermectin <i>vs</i>. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the united states |
| title_unstemmed | The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States |
| topic | Infectious Diseases, Epidemiology |
| url | http://dx.doi.org/10.1017/s0950268804003000 |